At present, stage IV non-sensitive mutations in non-small cell lung cancer (NSCLC) which means negative for actionable molecular markers of EGFR mutation, ALK,ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET has entered the splendid era of immunotherapy, while its application to unresectable locally advanced NSCLC is still being explored. This evidence concerns the gene ALK and non-small cell lung carcinoma.